Daily Pharmaceutical Industry Briefing

Xinjiang Hotan strengthens its TCM industry chain.

TCM 'going global'.

TCM.

As the world's largest producer and exporter of Active Pharmaceutical Ingredients (APIs), China supplies about one-third of global demand. However, after the pandemic-era surge in demand and prices, the industry is now undergoing a prolonged and painful cyclical adjustment. Plunging demand, capacity expansion, and homogenized competition have pushed many API products into a quagmire of persistent price declines and weak momentum. Wu Xionghui frankly admitted that industry competition has shifted from the past pursuit of 'First Launch' (being first to market) to 'Last Out' (last man standing wins), with the market increasingly exhibiting zero-sum characteristics.

'From the start of the year to now, our entire team has been on the road every month — covering markets across Asia, Africa, Latin America, Europe, and the US. Wherever you can imagine, we've been there.' During the 24th CPHI China, Wu Xionghui, Vice President of Hisun Pharmaceutical, described the current API market competition to a National Business Daily reporter as 'almost like going to war.' As the world's largest API producer and exporter, China supplies about one-third of global demand. However, after several years of pandemic-driven demand surges and price hikes, the industry is now undergoing a painful cyclical adjustment.

AI drug discovery.

Pharma companies.

As the world's largest producer and exporter of APIs, China supplies about one-third of global demand. However, after the pandemic-era surge in demand and prices, the industry is now undergoing a prolonged and painful cyclical adjustment. Plunging demand, capacity expansion, and homogenized competition have pushed many API products into a quagmire of persistent price declines and weak momentum. Wu Xionghui frankly admitted that industry competition has shifted from the past pursuit of 'First Launch' (being first to market) to 'Last Out' (last man standing wins), with the market increasingly exhibiting zero-sum characteristics. Per listed company disclosures...

Overview: As China's population ages, chronic disease incidence rises, and public health awareness strengthens, rigid demand in the pharmaceutical market continues to expand. According to the National Bureau of Statistics, in 2024 the number of above-scale pharmaceutical manufacturing enterprises in China reached 9,793, with total assets of CNY 51,746.1B, revenue of CNY 25,298.5B, and total profit of CNY 3,420.7B. Meanwhile, the normalization of centralized procurement has pushed traditional pharma companies to shift from 'scale expansion' to 'lean survival', accelerating the build-out of lean management systems across the entire industry chain, while pushing companies to transition from generic-drug dependence to innovation-driven transformation...

As a classic legacy drug, 'White & Black' (Baijiahei) has gradually faded from public view in recent years. Many netizens on social platforms have mentioned that 'White & Black is hard to find', 'many pharmacies no longer sell it', 'previously you could just register your ID card, now you need a prescription.' 'White & Black has been out of stock for a long time.' On July 1, when reporters called pharmacies in Shanghai, Guangzhou, and Chengdu, they received almost identical responses. An employee at a chain pharmacy in Guangzhou said that White & Black is still being sold, priced at CNY 15.5/box, but to purchase it, customers must bring the original prescription issued by a doctor and their own ID — the pharmacy needs to recover the prescription. As for the reason, the employee said...

Today, the topic 'the medicine Wu Xin wanted her assistant to buy was discontinued 6 years ago' shot to the top of the trending charts. On a variety show, Wu Xin lamented that she is really getting older: one day she casually asked her assistant to go buy her a box of 'White & Black' (Baijiahei), and the assistant was completely baffled, having no idea what she was talking about. After searching online, the assistant discovered that the drug had actually been discontinued six years ago. A young post-2000s guest beside them was also confused, saying they thought it was some kind of health supplement and didn't connect it to cold medicine at all. Many born in the 80s and 90s are very familiar with the classic ad slogan: 'Take white pills during the day, black pills at night.' According to Jiupai News, White & Black...

Capital inflows, technology landing — domestic Lu-177 adds new force. Farber Xintian (Fabor New Sky), a nuclear pharma startup invested by Lei Jun's Shunwei Capital, recently reached cooperation with the Dalian Institute of Chemical Physics (DICP) of the Chinese Academy of Sciences. Leveraging DICP's mature radioisotope separation and purification technology, the two parties will jointly build a ten-thousand-curie-level Lu-177 production line, accelerating the autonomous and controllable progress of radioisotope raw materials. Raw material bottlenecks, supply constraints, and high-priced isotopes — this was once the reality of domestic Lu-177 nuclear pharma development. As the core raw material for gastrointestinal pancreatic neuroendocrine tumors and late-stage prostate cancer RDC drugs, Lu-177 is currently the most commercially mature therapeutic...

Recently, the topic 'the medicine Wu Xin asked her assistant to buy was discontinued 6 years ago' trended online. On a variety show, host Wu Xin mentioned asking her assistant to buy 'White & Black' cold medicine, but the assistant responded 'I've never heard of it', saying it had supposedly been discontinued. The topic sparked heated discussion as soon as it emerged — many young netizens said they had never heard of 'White & Black', while many born in the 80s and 90s were very familiar with the classic ad slogan 'Take white pills during the day, black pills at night.' According to the NMPA official website, 'White & Black' corresponds to two sets of drug approval numbers: the generic names are Paracetamol Pseudoephedrine Hydrochloride Dextromethorphan Hydrobromide Tablets II (white pills) and Paracetamol...

On January 17, the National Healthcare Security Administration (NHSA) held a press conference titled 'Safeguarding People's Health, Empowering Economic Development', at which the spokesperson announced that the 11th batch of national drug centralized procurement would be carried out in 2025, with new batches of drug centralized procurement to be launched at an appropriate time. Provincial-level efforts would carry out nationally-Allianceed procurement with specialty characteristics. On March 5, 2025, the 'Government Work Report' clearly stated to 'optimize drug and consumable centralized procurement policies, strengthen quality assessment and supervision'. Subsequently, relevant national departments carried out a series of work on the centralized procurement optimization plan, including research, opinion solicitation, seminars, and expert demonstrations. In July, the NHSA at the State Council Information Office press conference clearly stated...

The NMPA General Department has published for public comment the 'Announcement on Optimizing Cell & Gene Therapy Drug Review and Approval Matters (Draft for Comments)'. The document mentions encouraging R&D innovation, improving clinical R&D quality and efficiency. Supporting clinical value-oriented cell & gene therapy drug R&D innovation, focused on malignant tumors, rare diseases, genetic disorders, immune system diseases, neurodegenerative diseases, and other key areas. It encourages global synchronized R&D and international multi-center clinical trials in China, including eligible cell & gene therapy drugs in the innovative drug clinical trial priority review 30-day channel, to improve clinical R&D...

On June 25, the Tengzhou Municipal Government Information Office held a press conference specifically briefing on the city's progress in 'promoting the implementation of centralized procurement policy and reducing the public's medical burden'. In response to a reporter's question about 'what impact and benefits have centralized procurement policies brought to hospitals and patients', Zhang Yanbo, Deputy Director of the Pharmacy Department of Tengzhou Central People's Hospital, gave a detailed answer. Zhang Yanbo stated that as a large regional comprehensive public hospital, the Central People's Hospital has fully and rigorously implemented centralized drug procurement work deployments at all levels, efficiently advancing the procurement and use of centralized-procurement drugs. For the hospital, the centralized procurement policy has promoted more standardized medication management. Currently, the hospital...

By Guan Yubing. The 12th batch of national organized drug centralized volume-based procurement was recently launched, with the bid opening expected in the near term. Data shows that the first 11 batches of national organized drug centralized procurement have already covered more than 490 drug products, and this round of procurement has screened 65 drugs, covering multiple therapeutic areas such as metabolism, cardiovascular, digestion, and oncology. Starting from last year's 11th batch of procurement, the NHSA proposed the principles of 'stabilizing clinical use, ensuring quality, preventing bid-rigging, and countering involution'. With further refinement of this round's rules, a clear signal has emerged: national drug centralized procurement is shifting from the 'lowest-price-only' one-way race toward...

As of 10:23 on June 29, 2026, Innovative Drug ETF Tianhong (517380) had a turnover rate of 2.82% in trading, with a turnover of CNY 45.0237M. The tracked Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drug Select 50 Index (HSSSHID) rose sharply by 7.13%, with constituent stocks 3SBio rising 16.67%, Biocytogen-B rising 16.64%, XtalPi Holdings rising 14.37%, Remegen, and other stocks following the rally. As of June 26, Innovative Drug ETF Tianhong (517380) saw a latest net inflow of CNY 13.9992M. Over the past 5 trading days...

The upcoming 12th batch of national drug centralized procurement requires that selected drugs carry out annual quality retrospective analysis as stipulated by drug regulatory authorities, and that product packaging not be downgraded during the agreement period. As of the first half of this year, more than 10 companies have been notified by drug regulatory authorities for production line issues and disqualified from the procurement selection by medical insurance authorities. Photo: Visual China. (Caixin) After centralized procurement of drugs and consumables brought price reductions that ease patients' burden, quality safety assurance is even more a matter of life and health. As of the first half of this year, more than 10 companies have been notified by drug regulatory authorities for production line issues and disqualified from procurement selection by medical insurance authorities. The most recent case, according to the Shandong...

Gelonghui, July 3 — The NMPA General Department has published for public comment the 'Announcement on Optimizing Cell & Gene Therapy Drug Review and Approval Matters (Draft for Comments)'. The document mentions encouraging R&D innovation, improving clinical R&D quality and efficiency. Supporting clinical value-oriented cell & gene therapy drug R&D innovation, focused on malignant tumors, rare diseases, genetic disorders, immune system diseases, neurodegenerative diseases, and other key areas. It encourages global synchronized R&D and international multi-center clinical trials in China, and includes eligible cell & gene therapy drugs in the innovative drug clinical trial priority review 30-day channel, improving clinical R&D...

The 12th batch of national procurement has arrived! On June 23, the Shanghai Sunshine Pharmaceutical Procurement Net released the 'No. 1 Announcement of the 12th National Organized Drug Centralized Volume-Based Procurement', officially announcing the scope of drug products and application-related requirements for this round of procurement. A total of 65 drug products were successfully included in the procurement scope. In addition, another 12 products participated in the preliminary pre-filling, but were not included in the 12th batch of procurement for various reasons. Shanghai Sunshine Pharmaceutical Procurement Net screenshot. Products marked with ★ in the 'Procurement Product Scope' are claimed to have patent disputes. If the enterprise cannot submit [proof of non-infringement] before the application deadline...

Medical insurance.

Medical insurance.

Pharmaceuticals.

To implement the decision-making deployments of the Party Central Committee and the State Council, strengthen the pharmaceutical retail industry's functions in professional services, health promotion, and emergency supply, and build a 'health station' that better serves people's medical and health needs, the following opinions are hereby put forward: I. Overall Requirements. Guided by Xi Jinping's Thought on Socialism with Chinese Characteristics for a New Era, fully implement the spirit of the 20th Party Congress and the successive plenary sessions of the 20th Central Committee, adhere to the combination of government guidance and market dominance, equal emphasis on innovation-driven and regulated development, actively optimize the policy environment, cultivate and expand business entities, and promote the professional, intensive, digitalized, and standardized development of the pharmaceutical retail industry...

A topic collection of domestic pharma & healthcare industry policies and regulations, updated weekly with the latest policy & regulatory developments in China's pharmaceutical & health sector, with in-depth interpretations of key industry policies — to help you stay on top of policy trends. According to PharnexCloud statistics, during June 15-21, 2026, multiple policies were released in China's domestic pharma & health industry. CDE issued two draft documents for public comment on overseas originator reference listed drugs; NMPA released a draft guideline on clinical evaluation of AI-assisted diagnostic medical devices; the Medical Device Technical Review Center published priority review results, with an extracorporeal cardiopulmonary support system approved...

Xinhua News Agency, Nanjing, June 23 — Liu Guozhong, member of the Political Bureau of the CPC Central Committee and Vice Premier of the State Council, conducted research in Jiangsu on June 22-23. He stressed the need to thoroughly study and implement the important instructions of General Secretary Xi Jinping, carry out the deployment of the Party Central Committee and the State Council, adhere to the strategic orientation of 'four orientations', strengthen innovation leadership and policy coordination, build biopharma as an emerging pillar industry, cultivate and develop brain-computer interface as a future industry, accelerate high-level scientific and technological self-reliance, continuously give birth to new quality productive forces, and provide strong support for the building of a Healthy China. Liu Guozhong successively visited Wuxi and Nanjing, going deep into biopharmaceutical, AI, cloud computing...

On June 23, the 12th batch of national procurement No. 1 document was finalized, including 65 products — high-frequency chronic disease drugs such as sacubitril/valsartan and dapagliflozin/metformin. 8 products marked with ★ must provide a non-infringement commitment, otherwise their online listing will be withdrawn; 12 products were not included, including lidocaine/prilocaine, three assisted-reproduction products, and shortage drugs. In particular, centralized procurement rules were comprehensively upgraded: patent compliance as a hard threshold, anchor settings to curb ultra-low pricing, companies must submit five-year production records and capacity certification, overseas generics must pass China GMP inspections, medical groups directly report volumes for the first time, and centralized procurement is tied to tiered diagnosis and treatment. Ruice interpretation: the 12th batch of centralized procurement...

Looking back at October, the overall chemical market showed a pattern of more declines than gains. According to monitoring data from Guanghuajun, in October there were 85 raw materials with price increases and 147 raw materials with price declines. October chemical market overview: In October, the chemical market once again entered the traditional 'Silver October' test period, but from a data perspective, the overall market did not see the warmth expected. This year, from polyester to polyolefin industry chains, demand recovery has shown a 'weak strength, slow pace' feature — multiple interviewees said that the expected recovery of demand faces multiple challenges. While market demand remains weak, the chemical industry's overcapacity problem is becoming increasingly serious.

Which professional pivaloyl chloride agrochemical intermediate / pharmaceutical-grade pivaloyl chloride manufacturers on the market are worth recommending? What are the core advantages and product features of these companies? How should enterprises of different scales and industries choose the right pivaloyl chloride supplier? What are the future development trends of the pivaloyl chloride industry? Conclusion summary: This article focuses on the pivaloyl chloride agrochemical intermediate / pharmaceutical-grade pivaloyl chloride industry, recommending 5 professional manufacturers including Shandong Jiahong Chemical Co., Ltd. Shandong Jiahong Chemical has been deeply engaged in the chemical field for over 30 years, with a comprehensive product system and deep technical...

China Chemical News — Last week (June 22-26), most oil & chemical indices declined; the oil index declined across the board, while the chemical index was split. Specifically: the chemical raw material index rose a cumulative 1.87%; the chemical machinery index fell a cumulative 0.30%; the chemical pharma index rose a cumulative 2.34%; the pesticide & fertilizer index fell a cumulative 1.88%; in the oil sector, the oil refining index fell a cumulative 2.13%, the oil extraction index fell a cumulative 4.88%, and the oil trading index fell a cumulative 7.93%. Last week, affected by the easing of Middle East tensions, international crude oil prices oscillated downward.

The China Federation of Logistics & Purchasing released market price monitoring data for 50 important commodities nationwide. The statistical period was June 15-18, 2026, with prices showing a mixed up-down pattern. Overall, of the 50 monitored products, 21 saw price increases month-on-month (42% of the sample); 23 saw price declines (46%); the remaining 6 remained flat (12%) — the number of declining products slightly exceeded that of rising products.

On July 2, the 190,000 t/y high-end fine chemical new materials renovation and expansion project of Jiangsu Oxiranchem (a subsidiary of Oxiranchem (9.060, -0.08, -0.88%)) held its groundbreaking ceremony at the Yangzhou Chemical Industry Park. Zhu Zongjiang, President of Oxiranchem, stated that ethylene oxide-derived fine new materials are the core track the company has been deeply engaged in for over 40 years, and new energy electrolyte solvents are the 'core strategic pillar' of the company's high-end, green, materials-based, and intelligent '15th Five-Year Plan'. Oxiranchem will take the start of this project as an opportunity to continue deepening its main ethylene fine new materials business, relying on its proprietary core technologies to continuously iterate products and constantly break through...

According to statistics from the China Petroleum and Chemical Industry Federation, the total output value of China's fine chemicals industry in 2025 approached CNY 7 trillion, accounting for more than 40% of global fine chemicals output value, with an average annual growth rate stable at around 6%, two percentage points higher than the global fine chemicals average annual growth rate of 4%. Currently, the domestic fine chemicals industry has shown a clear layout feature of 'eastern aggregation, central and western upgrading': the Yangtze River Delta and Pearl River Delta regions, with their mature industrial clusters and technological advantages, are focused on high value-added fine chemical tracks such as high-end electronic chemicals and pharma intermediates; the Bohai Rim region emphasizes R&D and commercialization of new materials...

China Net Finance, June 29 — In the first half of 2026, the energy industry experienced a round of price-repair rally from the bottom. Since Q2, affected by multiple factors including escalation of Middle East geopolitical tensions, tightening of domestic safety regulation and production limits, and earlier-than-usual peak-summer demand, the price center for coal, natural gas, and coal chemical products has risen significantly from Q1, with a clear upward inflection point in earnings for resource-based companies. On the evening of June 29, Guanghui Energy (600256.SH) announced its 2026 half-year profit forecast. The company expects January-June net profit attributable to shareholders to reach CNY 1.17B...

The current situation is gradually becoming clearer, and the previously highly-avoided uncertainty has been significantly improved, notably boosting market confidence in participating in the petroleum & petrochemical and chemical sectors. 2. High-frequency data tracking of chemical industry operations. Industry chain operating rates: Affected by previous oil price volatility and uncertainty in raw material supply, multiple segments of the chemical industry chain saw operating-rate reductions. With both active and passive factors at play, inventories of most products have continued to decline over the past two-plus months, with operating rates across segments falling notably from pre-war levels: teapot and major refinery operating rates dropped 3 and 15 percentage points respectively from pre-war levels, with current teapot operating rates...

On July 2, the 190,000 t/y high-end fine chemical new materials renovation and expansion project of Jiangsu Oxiranchem (a subsidiary of Liaoning Oxiranchem Co., Ltd.) held its groundbreaking ceremony at the Yangzhou Chemical Industry Park. Zhu Zongjiang, President of Oxiranchem, along with the company's management, project construction, and technology R&D teams, and Yizheng City park management leaders, jointly attended the groundbreaking ceremony. With a 12-month construction period and based on existing plant area for technical renovation and expansion, the project, once fully operational, will form a complete capacity matrix: 90,000 t/y battery-grade EC, 10,000 t/y industrial-grade EC, supported by 80,000 t/y ethylene glycol butyl ether, 5,000 t/y ethylene glycol methyl ether, 5,000 t/y ethylene glycol...

Securities Daily — On June 22, Zhaoxin Co. stated on the interactive platform in response to investor questions that its market cap is comprehensively affected by multiple external factors such as macro environment and industry cycle. The company continues to deepen its two main businesses — new energy and fine chemicals — continuously optimizing operation models, promoting technological innovation, strictly controlling costs to improve quality and efficiency, and consolidating the company's intrinsic value. At the same time, it conducts investor communication work on a regular basis, objectively and timely conveying the fundamentals of the company's operations. The company will continue to improve market-cap management-related work, promote full reflection of the company's intrinsic value, and effectively safeguard the long-term legal rights and interests of all shareholders.

On the market, Shenzhen stocks opened higher and continued higher, Shanghai stocks opened higher and oscillated, with the chemical concept sector advancing. Regarding related ETFs, Chemical ETF Tianhong (159133) underlying index rose 1.55% intraday, with subscriptions reaching 1M lots; turnover reached CNY 24.3128M; turnover rate reached 1.18%. Among the constituent stocks, Chuanfa Dragon Phosphorus, Longbai Group, and Hangyang Co. rose more than 5%, with Duofudo, Capchem, Tai Energy Chemical and other stocks following the rally. Chemical ETF Tianhong (159133) closely tracks the Sub-Industry Chemical Index, which over the past year...

(1) In order to implement the Environmental Protection Law of the People's Republic of China and other relevant laws and regulations, prevent and control environmental pollution, protect ecological security and human health, and promote progress in pharmaceutical industry production processes and pollution treatment technologies, this technical policy is hereby formulated. (2) This technical policy is a guidance document for the management, design, construction, production, scientific research, and other work of construction projects and existing enterprises of relevant units for reference and adoption; this technical policy is applicable to the pharmaceutical industry (including veterinary drugs). (3) The pharmaceutical industry is encouraged to develop on a scale and intensive basis, improving industrial concentration and reducing the number of pharmaceutical enterprises. SMEs are encouraged to move toward 'specialized, refined'...

Sinopharm Engineering Environmental Company, as the core business segment of Sinopharm (Group) United Engineering Co., Ltd. (Sinopharm Engineering), has for nearly 20 years focused on the pharmaceutical chemical environmental protection field, using technology as a blade to break through industry challenges and innovation as a shield to build a green barrier. Its development trajectory is not only a reflection of the era of continuous deepening of national environmental protection policy, but also a vivid practice of the pharmaceutical chemical industry's leap toward 'green transformation'. Sinopharm Engineering positions its environmental protection business as a 'strategic emerging segment', giving priority tilt from capital, technology, and talent. Through internal resource integration, it quickly built a 'design - equipment - engineering' framework...

Article 2: Activities related to drug R&D, production, distribution, use, and supervision management shall adhere to a people-centered approach, follow scientific laws and ethical principles, and comprehensively prevent and control risks. Article 3: The state improves the drug innovation system, supports the R&D and innovation of drugs oriented toward clinical value, encourages research and creation of new drugs, supports the clinical promotion and use of new drugs; promotes the inheritance and innovation of traditional Chinese medicine, and gives full play to the role of TCM in prevention, medical treatment, and healthcare; promotes the R&D and innovation of generic drugs, and improves the quality and efficacy of generic drugs. Article 4: Departments of people's governments at or above the county level that are responsible for drug supervision and administration (hereinafter referred to as drug supervision departments)...

The U.S. Food and Drug Administration has launched the PreCheck pilot program to accelerate the review process. Affected by this news, U.S. biopharma stocks rose in after-hours trading. After-hours gains of related stocks: EQ +9.4%, ADMA +0.96%, PFE +0.16%. Translation content by third-party software. Disclaimer: The market is risky and investment requires caution. This article is generated by an AI large model based on public information and does not represent the views of Sina Finance. All information, data and charts are for reference only and do not constitute any form of investment advice or decision basis. The relevant information is subject to the actual announcement.

China Youth Daily Client, Guangzhou, June 29 (China Youth Daily - China Youth Network reporters Jia Jieye, Lin Jie, Pan Yuan, trainee reporter Yang Lei) — Today, the 2026 'Vibrant China Research Tour' Guangdong Station themed interview was launched in Guangzhou. As a pharmaceutical industry expert, Tang Lida, Vice President of Beijing Future Pharmaceutical Industry Chain Research Institute, gave a speech at the briefing on the development of the biopharma industry in the Guangdong-Hong Kong-Macau Greater Bay Area. Tang Lida suggested in his speech: further deepen regulatory coordination and data interoperability between Guangdong, Hong Kong, and Macau in the biopharma sector. In 2021, Guangdong Province officially implemented the 'Hong Kong-Macau Drug and Medical Device Pass' policy. According to 'Hong Kong-Macau Drug and Medical Device Pass'...

On June 29, the long-quiet A-share and HK-share pharma sectors saw a powerful eruption. At close, the SW Pharma & Biological Index surged nearly 6% to a high; the HK-share Hang Seng Biotech Index (HSBIO) soared more than 7%. On the trading board, A-share innovative drugs, CXO (pharma outsourcing), and biological products all flew red across the board — Guangshengtang, Wanbang Pharma, 3SBio, Shoutai Shen and others hit the 20CM upper limit; Tailong Pharmaceutical, Shuanglu Pharmaceutical, and Kangyuan Pharmaceutical among more than ten TCM and chemical pharma stocks were sealed at the limit. On the HK side, Remegen (09995.HK) rose more than 15%, with CSPC Pharma, WuXi Biologics, Innovent Biologics all rising...

The State Administration for Market Regulation (SAMR) recently held its second 2026 enterprise fair competition symposium. Heads of 7 enterprises from manufacturing, AI, pharma, construction, and other fields exchanged views on 'breaking through various bottlenecks and choke points and safeguarding market fair competition'. Meng Yang, Party member and Deputy Director of SAMR, presided over the symposium and delivered a speech. After listening to the opinions and suggestions of the enterprise heads, Meng Yang responded to the relevant situation and introduced the policy measures issued by SAMR in strengthening anti-monopoly enforcement and improving fair competition governance, as well as the main work carried out. He pointed out that SAMR will deeply implement the decision-making and deployment of the Party Central Committee...